Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054795 · ClinicalTrials.gov registry record · Phase 3

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

A Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms, sponsored by Pharmacyclics.

Completed
Registry status
Phase 3
Development phase
550
Enrollment target
20
Study locations

NCT00054795: Completed Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms, sponsored by Pharmacyclics.

NCT00054795 is a Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms that has completed, run by Pharmacyclics. The registered enrollment target is 550 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054795, a Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms, has completed, sponsored by Pharmacyclics.

COMPLETED
Registry status
Phase 3
Development phase
550 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.

Conditions Studied

Carcinoma, Non-Small Cell Lung Brain Neoplasms Metastases, Neoplasm

Interventions

  • DRUG Motexafin Gadolinium

Study Locations (20)

California

  • - Berkeley
  • - Concord
  • - Greenbrae
  • - Los Angeles
  • - Montebello
  • - Sacramento
  • - Stanford

Arkansas

  • - Fort Smith
  • - Little Rock

Connecticut

  • - Hartford
  • - New Haven

Indiana

  • - Fort Wayne
  • - Indianapolis

Maryland

  • - Baltimore
  • - Washington D.C

Arizona

  • - Phoenix

Colorado

  • - Aurora

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 550 participants
Phase Phase 3
Pharmacyclics

54 total trials

What the finished NCT00054795 record still lists

NCT00054795 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% higher).

The record links to 3 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Motexafin Gadolinium is the first listed.

NCT00054795 names 20 study sites across 10 states, led by California, Arkansas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00054795 about?

NCT00054795 is a clinical study titled "Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)". The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain...

What is the current status of trial NCT00054795?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 550 participants.

What conditions does trial NCT00054795 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Brain Neoplasms, Metastases, Neoplasm.

What interventions are being tested in trial NCT00054795?

The interventions under investigation include: Motexafin Gadolinium (DRUG).

Who is sponsoring clinical trial NCT00054795?

This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00054795 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00054795's enrollment target sits among peer trials

550 26th of 130 higher than 105 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01852448 · 550 participants

    Genetics of Insulin and Incretins in Cystic Fibrosis

  • NCT02995252 · 550 participants

    The HOPE Study: Characterizing Patients With Hepatitis B and C

  • NCT03474913 · 550 participants

    Upright MRI for Prostate Cancer Screening

  • NCT04761120 · 550 participants

    Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

Related registry views

Source: ClinicalTrials.gov NCT00054795, the US trial registry maintained by the National Library of Medicine. NCT00054795 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.